⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INKT News
MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
globenewswire.com
INKT
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
prnewswire.com
GTBP
IPHA
INKT
IPSC
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
globenewswire.com
INKT
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
globenewswire.com
INKT
Form 8-K
sec.gov
INKT
IBRX
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
globenewswire.com
INKT
IBRX
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
globenewswire.com
INKT
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
globenewswire.com
INKT
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
businesswire.com
AGEN
INKT
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
globenewswire.com
INKT